Floatz Rating
B62/100
Confidence
Indicative
Sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Modality
Small molecule
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
61High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07208344CT.gov Intravenous Infusion of Umbilical Cord Blood as an Adjunctive Treatment for Alzheimer's Disease | — | Recruiting | — | — | — |
NCT05518409CT.gov Immunohistochemical Study of Neurodegenerative Diseases | — | Unknown | — | — | — |
NCT03441516CT.gov Effect of Choline Alphoscerate on Cognitive Function in Alzheimer's Dementia | — | Unknown | — | — | — |
NCT01255046CT.gov Study of STA-1 as an Add-on Treatment to Donepezil | — | Unknown | — | — | — |
NCT01487395CT.gov Prediction of Cognitive Properties of New Drug Candidates for Neurodegenerative Diseases in Early Clinical Development | — | Completed | — | — | — |
NCT00777608CT.gov A Study to Test the Performance of the CogState Computerized Neuropsychological Battery in Patients With Alzheimer's Disease (0000-086)(COMPLETED) | — | Completed | — | — | — |
NCT00710684CT.gov A Study of SB-742457, Added to Donepezil for the Treatment of Mild-to-moderate Alzheimer's Disease | — | Completed | — | — | — |
NCT01297036CT.gov Pharmacokinetic Comparisons of Two Donepezil Formulations | — | Completed | — | — | — |
NCT00563732CT.gov Study Evaluating Potential Pharmacokinetic (PK) Interaction Between Lecozotan and Digoxin | — | Completed | — | — | — |
NCT00499642CT.gov Study Evaluating the Effect of Lecozotan SR on the QTc Interval | — | Completed | — | — | — |
Show 5 more trialsShow fewer
NCT00494962CT.gov Study Comparing Lecozotan SR Two 5-mg Tablets Vs. Lecozotan SR One 10-mg Tablet in Healthy Subjects | — | Completed | — | — | — |
NCT00366483CT.gov Study Evaluating the Safety of Lecozotan SR in Healthy Young and Elderly Subjects | — | Completed | — | — | — |
NCT00277810CT.gov Study Evaluating the Safety, Tolerability, and Efficacy of Lecozotan SR in Outpatients With Alzheimer's Disease | — | Completed | — | — | — |
NCT00151398CT.gov Study Evaluating Lecozotan SR in Mild to Moderate Alzheimer's Disease (AD) | — | Completed | — | — | — |
NCT00151333CT.gov Study Evaluating SRA-333 in Mild to Moderate Alzheimer's Disease (AD) | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Alzheimer Disease
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Lecozotan (this asset) | Wyeth is now a wholly owned subsidiary of Pfizer | P1 | B · 62 |
| 4-((1E)-2-(6-(2-)2-(2-FLUOROETHOXY)ETHOXY)ETHOXY)PYRIDIN-3-YL)ETHENYL)-N-METHYLBENZENAMINE | Akiva Mintz | P4 | BBB |
| Memantine | Carnot Laboratories | P4 | BBB |
| Escitalopram | NYU Langone Health | P4 | BBB |
| Flortaucipir | Eli Radiopharma | P4 | BBB |
| Rivastigmine | Anhui Provincial Hospital | P4 | BBB |
| Florbetaben | National Institute of Mental Health (NIMH) | P4 | BBB |
| 6H-BENZOFURO(3A,3,2-EF)(2)BENZAZEPIN-6-OL, 4A,5,9,10,11,12-HEXAHYDRO-3-METHOXY-11-METHYL-, (4AS,6R,8AS) | Anhui Provincial Hospital | P4 | BBB |
| Sertraline | AstraZeneca | P4 | BBB |
+42 more in the Alzheimer Disease cohort
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Lecozotan in Alzheimer Disease. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/lecozotan-alzheimer-disease
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →